Continuous subcutaneous glucose monitoring (CGM) use is increasing in diabetes care. Still there are concerns with regard to sensor accuracy especially at night.
Aim of the Study: To assess accuracy of commonly used CGM systems at a 2 week diabetes camp in children with type 1 diabetes (T1D) ages 9-14 years.
Out of 38 children, 37 routinely wore a CGM system throughout the camp. Baseline characteristics: age 11.0 (9.9;12.1) years; 57% girls; HbA1c 7.2% (6.9; 7.7); diabetes duration 3.6 (2.7; 6.3) years (median (interquartile range)). Capillary glucose measurements were performed prior to main meals, at bedtime and whenever deemed necessary by medical staff after thoroughly cleaning the finger tips. Calibrations of Medtronic Enlite was performed twice daily when glycemia was stable. All concomitantly available data pairs were used for the analysis. Night-time was defined as period when children were supposed to be in bed (10 PM until 7 AM).
Sensor distribution: 51% Abbott Libre, 35% Medtronic Enlite, 14% Dexcom G6.
CGM accuracy shown in Table 1: MARD in % (interquartile range)).
Sensor performance of the adequately calibrated Medtronic system outperformed the factory-calibrated sensors in most situations. All sensors performed worse in hypoglycaemia. During the nights the MARD was higher, potentially due to pressure artefacts.
B. Rami-Merhar: Advisory Panel; Self; Abbott. Speaker’s Bureau; Self; Eli Lilly and Company, Medtronic. K. Nagl: None. G. Berger: None. A. Schütz: None. F. Aberer: None. J.K. Mader: Advisory Panel; Self; Becton, Dickinson and Company, Eli Lilly and Company, Medtronic, Prediktor Medical, Sanofi-Aventis. Speaker’s Bureau; Self; Abbott, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Roche Diabetes Care, Sanofi-Aventis.